WO2003048302A3 - Identifying anti-tumor targets or agents by lipid raft immunization and proteomics - Google Patents

Identifying anti-tumor targets or agents by lipid raft immunization and proteomics Download PDF

Info

Publication number
WO2003048302A3
WO2003048302A3 PCT/US2002/032493 US0232493W WO03048302A3 WO 2003048302 A3 WO2003048302 A3 WO 2003048302A3 US 0232493 W US0232493 W US 0232493W WO 03048302 A3 WO03048302 A3 WO 03048302A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
immunization
identifying anti
proteomics
tumor targets
Prior art date
Application number
PCT/US2002/032493
Other languages
French (fr)
Other versions
WO2003048302A2 (en
Inventor
Yun J Tso
Green Jennifer Mcphate
Original Assignee
Protein Design Labs Inc
Yun J Tso
Green Jennifer Mcphate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc, Yun J Tso, Green Jennifer Mcphate filed Critical Protein Design Labs Inc
Priority to AU2002340169A priority Critical patent/AU2002340169A1/en
Publication of WO2003048302A2 publication Critical patent/WO2003048302A2/en
Publication of WO2003048302A3 publication Critical patent/WO2003048302A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids

Abstract

The present invention is directed to a method for identifying anti-tumor targets by examining lipid rafts. It provides for a method for identifying anti-tumor targets by lipid raft proteomics and a method for identifying anti-tumor agents by lipid rafts immunization. It also provides for hybridomas produced by the method of identifying anti-tumor agents by lipid raft immunization, and antibodies produced by the hybridomas. It also provides for the anti-tumor targets or agents identified by the methods in the present invention.
PCT/US2002/032493 2001-10-11 2002-10-10 Identifying anti-tumor targets or agents by lipid raft immunization and proteomics WO2003048302A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002340169A AU2002340169A1 (en) 2001-10-11 2002-10-10 Identifying anti-tumor targets or agents by lipid raft immunization and proteomics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32917801P 2001-10-11 2001-10-11
US60/329,178 2001-10-11
US33196501P 2001-11-21 2001-11-21
US60/331,965 2001-11-21

Publications (2)

Publication Number Publication Date
WO2003048302A2 WO2003048302A2 (en) 2003-06-12
WO2003048302A3 true WO2003048302A3 (en) 2004-09-02

Family

ID=26986685

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2002/032492 WO2003047623A1 (en) 2001-10-11 2002-10-10 Treatment of prostate cancer by inhibitors of ncam2
PCT/US2002/032491 WO2003048301A2 (en) 2001-10-11 2002-10-10 Anti-hla-dr antibodies and the methods of using thereof
PCT/US2002/032494 WO2003030831A2 (en) 2001-10-11 2002-10-10 Treatment of prostate cancer by inhibitors of atp synthase
PCT/US2002/032493 WO2003048302A2 (en) 2001-10-11 2002-10-10 Identifying anti-tumor targets or agents by lipid raft immunization and proteomics

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2002/032492 WO2003047623A1 (en) 2001-10-11 2002-10-10 Treatment of prostate cancer by inhibitors of ncam2
PCT/US2002/032491 WO2003048301A2 (en) 2001-10-11 2002-10-10 Anti-hla-dr antibodies and the methods of using thereof
PCT/US2002/032494 WO2003030831A2 (en) 2001-10-11 2002-10-10 Treatment of prostate cancer by inhibitors of atp synthase

Country Status (3)

Country Link
US (4) US6894149B2 (en)
AU (3) AU2002340168A1 (en)
WO (4) WO2003047623A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
JP2005502030A (en) * 2001-05-29 2005-01-20 リージェンツ オブ ザ ユニバーシティ オブ ミシガン Protein analysis system and method
US6894149B2 (en) 2001-10-11 2005-05-17 Protein Design Labs, Inc. Anti-HLA-DA antibodies and the methods of using thereof
US20030100828A1 (en) * 2001-11-29 2003-05-29 Siemens Aktiengesellschaft Method for minimally invasive prostate tumor treatment
FR2844513B1 (en) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement ANTIBODIES FOR ADCC AND INDUCING PRODUCTION OF CYTOKINS.
FR2844455B1 (en) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
US7399835B2 (en) 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
CA2538141A1 (en) * 2003-09-09 2005-03-17 Gpc Biotech Ag Therapeutic human anti-mhc class ii antibodies and their uses
CA2542840A1 (en) * 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US20080057057A1 (en) * 2004-03-18 2008-03-06 Applied Research Systems Ars Holding N.V. Anti-Lipid Rafts Antibodies
US7411046B2 (en) * 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
AU2007218959A1 (en) * 2006-02-24 2007-08-30 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
KR100862904B1 (en) * 2006-07-20 2008-10-13 주식회사 서린바이오사이언스 Microchip for Protein Fixation
WO2009152319A1 (en) * 2008-06-13 2009-12-17 Synvista Therapeutics, Inc. Reagents and methods for detecting a polymorphic protein
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
CN102464720A (en) * 2010-11-12 2012-05-23 苏州工业园区晨健抗体组药物开发有限公司 Preparation method and use of chimeric human anti-murine monoclonal antibody for inhibiting angiostatin acceptor
US10969392B2 (en) * 2015-12-10 2021-04-06 Vanderbilt University Methods and systems for predicting response to immunotherapies for treatment of cancer
EP3655440A4 (en) * 2017-07-20 2021-10-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting cd33-expressing cancers
CN108640995A (en) * 2018-04-03 2018-10-12 厦门大学 A kind of preparation method of anti-human leukaemia cell KG-1 compendency monoclonal antibodies
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
KR20230156921A (en) 2021-03-12 2023-11-15 젠맵 에이/에스 Non-activating antibody variants

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) * 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5552530A (en) 1987-08-27 1996-09-03 Eli Lilly & Company Antibodies that specifically bind to and inhibit human synovial phospholipase A2 type A
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5004432A (en) * 1989-10-02 1991-04-02 Raychem Corporation Electrical connector
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
DE4005630A1 (en) * 1990-02-22 1991-09-05 Behringwerke Ag Monoclonal antibodies against tumour-associated antigens - specifically MAB BW SCLC-1 and MAB BW SCLC-2, used in immune therapy and treatment and diagnosis of tumours
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE143509T1 (en) 1990-06-21 1996-10-15 Honeywell Inc VARIABLE HORIZON BASED ADAPTIVE CONTROL WITH MEANS OF MINIMIZING OPERATING COSTS
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009293A1 (en) * 1990-11-23 1992-06-11 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
DE4212706A1 (en) * 1992-04-16 1993-10-21 Behringwerke Ag Diagnostic method for the immunological determination of one or more analytes
CA2144750A1 (en) * 1992-09-17 1994-03-31 Rolf Stahel Tumor-specific antibodies and antigen
US5591432A (en) * 1993-02-17 1997-01-07 Becton, Dickinson And Company Antibody to the neural cell adhesion molecule and methods of use
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
AU4256096A (en) 1994-12-07 1996-06-26 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity
US5985822A (en) * 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
DE19531346A1 (en) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Medicines for immunotherapy, containing antibodies that specifically recognize the MHCII antigen of a patient to be treated
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
DE19647426C1 (en) * 1996-11-15 1998-06-25 Gsf Forschungszentrum Umwelt Human colon carcinoma cell lines with stable HSP72 expression
US6020474A (en) * 1997-01-15 2000-02-01 Incyte Pharmaceuticals, Inc. ATP synthase subunits
US5786150A (en) * 1997-03-11 1998-07-28 Incyte Pharmaceuticals, Inc. F0 ATP synthase subunit
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
JP2002513804A (en) * 1998-05-05 2002-05-14 アドヘレックス テクノロジーズ インコーポレイテッド Compounds and methods for modulating non-classical cadherin-mediated functions
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US20020102264A1 (en) * 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
US6894149B2 (en) 2001-10-11 2005-05-17 Protein Design Labs, Inc. Anti-HLA-DA antibodies and the methods of using thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAVIE ET AL: "Up-regulation of caveolae and caveolar constituents in multidrug resistant cancer cells", J. OF BIOLOGICAL CHEMISTRY, vol. 273, no. 49, 4 December 1998 (1998-12-04), pages 32380 - 32383, XP002978701 *
SIMONS ET AL: "Lipid rafts and signal transduction", NATURE REVIEWS/MOLECULAR CELL BIOLOGY, vol. 1, October 2000 (2000-10-01), pages 31 - 41, XP001006200 *
YANG ET AL: "Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells", FEBS LETTERS, vol. 439, 1998, pages 368 - 372, XP004258689 *

Also Published As

Publication number Publication date
AU2002340167A1 (en) 2003-06-17
WO2003048302A2 (en) 2003-06-12
WO2003048301A2 (en) 2003-06-12
WO2003048301A3 (en) 2004-03-04
AU2002340169A1 (en) 2003-06-17
US20030082188A1 (en) 2003-05-01
WO2003030831A2 (en) 2003-04-17
US20030086929A1 (en) 2003-05-08
WO2003047623A1 (en) 2003-06-12
US20030138862A1 (en) 2003-07-24
US20030096285A1 (en) 2003-05-22
AU2002340168A1 (en) 2003-06-17
US6894149B2 (en) 2005-05-17
AU2002340167A8 (en) 2003-06-17
AU2002340169A8 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003048302A3 (en) Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
WO2003014325A3 (en) Protein design automation for protein libraries
WO2000023564A3 (en) Protein design automation for protein libraries
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2003039470A3 (en) Polyvalent immunogen of hiv
WO2002092782A3 (en) Diagnosis and treatment of malignant neoplasms
EP1348961A4 (en) Protein chips, method producing it and detection system of the protein chips, and operating method of the detection system
WO1999065947A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
WO2004046182A3 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
WO2002090989A3 (en) Method for detecting blood cell antigens and the antibodies in response to the same
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
AU4908799A (en) Determination of the hydrophobic pulmonary surfactant protein sp-c
WO2001051926A3 (en) Competitive enzyme immunoassay for assessing total antigen content of aluminum-adsorbed antigens
EP1621555A4 (en) Immunogen, composition for immunological use, and method of producing antibody using the same
WO2002086505A3 (en) Intracellular analysis
AU2001267922A1 (en) Method of assaying the function of fc fragment of antibody
WO1999061906A3 (en) Toxoplasma gondii antigens, p35, and uses thereof
WO2003014386A3 (en) Method for identifying macrocyclic polyketides
AU2003285298A1 (en) Method and kit for detecting antigens
WO2004045371A3 (en) Methods for diagnosing the presence or stage of cancer
WO2001085989A3 (en) Hypha-specific factors from candida albicans

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP